DaysToHappy announced the launch of Happy 2.0, a revolutionary mental health platform designed to help HR leaders and university administrators address rising rates of depression and anxiety among employees and students—at scale,…
Inogen, a leading medical technology company specializing in innovative respiratory products for homecare use, today announced the launch of VoxiTM 5, a new stationary oxygen concentrator (SOC) designed to enhance access to…
ZEISS Vision Care US Appoints Healthcare Industry Veteran Gary Rosenblum as President and CEO ZEISS Vision Care, one of the world’s leading manufacturers of eyeglass lenses and ophthalmic instruments, announced…
Compass One Healthcare has announced its signature Healthcare Technology Management (HTM) brand: Intelas. Healthcare is evolving rapidly, and the need for integration, standardization, and scale is growing with it. Intelas exemplifies…
In response to Harbour BioMed’s recent press release regarding a decision in its pending lawsuit, Biocytogen is issuing the following statement: Biocytogen operates in accordance with its core values: independent innovation,…
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the launch of its DIRECT-AI registry study. This study will assess how the ArteraAI Prostate Test influences treatment decision-making…
Fresenius Medical Care Launches FME Reignite with Profit Boost and New Investment Plan Fresenius Medical Care (FME), the world’s leading provider of products and services for people with kidney disease,…
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the…
Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in the field of urology. The peer-reviewed study highlights…
Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided…
a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial…
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced new data from its preclinical study of ZL-1503, the Company’s promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory…